REPLICATION,VIRULENCE & IMMUNOGENICITY IN RECOMBINANT RESPIRATORY SYNCYTIAL V
REPLICATION,VIRULENCE & IMMUNOGENICITY IN RECOMBINANT RESPIRATORY SYNCYTIAL V
批准号:
6098927
负责人:
PETER LEON COLLINS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Pneumovirus vaccine attenuated microorganism complementary DNA gene mutation laboratory mouse live vaccine microorganism culture nucleocapsid recombinant virus respiratory syncytial virus site directed mutagenesis tissue /cell culture transfection vaccine development virulence virus antigen virus cytopathogenic effect virus genetics virus protein virus replication
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Human respiratory syncytial virus (RSV) is an
important agent of pediatric respiratory tract disease worldwide and
is responsible for a huge burden of morbidity and significant
mortality. There is no licensed vaccine. Obstacles to vaccine
development include the poor growth of the virus in cell culture,
the semi- permissive nature of the infection in convenient
experimental animals, and the difficulty of achieving an appropriate
balance between immunogenicity (which depends on reasonable
levels of virus replication) and attenuation (which depends on
reduced levels of virus replication). We recently developed a
method for producing RSV by the intracellular coexpression of
cDNAs encoding a complete RSV replicative intermediate RNA
(antigenome) and the N, P, L and M2-1 proteins, which together
constitute a nucleocapsid that is fully competent for RNA synthesis.
This provides an important tool for basic molecular and
pathogenesis studies as well as a method for fine-tuning the level of
attenuation of candidate vaccine viruses. RSV encodes ten mRNAs
encoding eleven proteins (the M2 mRNA contains two overlapping
ORFs encoding two separate proteins, M2- 1 and M2-2). We
investigated whether individual RSV genes could be ?knocked out?
without ablating the ability of the virus to grow in cell culture. To
date, four RSV genes can be individually knocked out without loss
of infectivity, namely NS1, NS2, SH and G. This was done in two
cases (NS1 and NS2) by introducing stop codons into the
translational open reading frame (ORF), and in all four cases also
was done by completely deleting the gene, such that the genome is
shorter and encodes one fewer mRNA. The NS1 knockout virus
grows somewhat less well than the parent in cell culture, and its
analysis is in progress. The NS2 knockout virus grows somewhat
more slowly than does the wild type parent in a single step growth
curve and forms pinpoint plaques. The version of the NS2
knockout virus in which stop codons had been introduced exhibits
reversion to an NS2+ phenotype by reversion of the stop codons to
sense. This was not observed with the gene deletion, illustrating its
stability against reversion. The SH knockout virus forms plaques
that were larger than wild type, and it grows as well or slightly
better than wild type in cell culture in a single step growth curve. In
mice, the SH knockout grew as well as wild type in the lower
respiratory tract but was significantly restricted in the upper
respiratory tract. It was equivalent to wild type with regard to the
ability to induce RSV-specific serum antibodies and protection
against challenge virus replication. In chimpanzees, the only
experimental animal which approaches humans with regard to
permissiveness for RSV infection and disease, the SH knockout
virus was only slightly attenuated. Interestingly, however, it was
associated with significantly reduced disease, i.e. rhinorrhea, which
would be an ideal feature for a live-attenuated vaccine virus. The G
knockout virus grows less well than its wild type parent in cell
culture. Nonetheless, it does form plaques and can be propagated.
The fact that its attachment activity is not essential for in vitro
growth implies that one of the other surface glycoproteins can serve
an auxiliary attachment function. We showed that RSV can accept
the insertion of sequence encoding an additional, foreign mRNA.
Chimeric genes were constructed in which the ORF encoding
chloramphenicol acetyl transferase (CAT), green fluorescent
protein (GFP) or luciferase (LUC) was engineered to be flanked by
the RSV gene-start (GS) and gene-end (GE) transcription signals.
Each transcription cassette was inserted into the leader-NS1, SH-G
or F-M2 junctions in the antigenomic cDNA. Infectious
recombinant viruses which each contained one foreign insert were
recovered. Each foreign gene was expressed as an additional
mRNA, and each protein was expressed to a level comparable to
that of the RSV proteins. The presence of the short CAT or GFP
genes (~750 bp) resulted in a small decrease in plaque size and a
20-fold reduction in virus yield. In contrast, the presence of the
longer (~1750 bp) LUC gene reduced virus growth to the point that
the virus could be propagated but not significantly amplified. This
shows that the insertion of an additional gene can be a method of
attenuation that appears to be length-dependent. We hypothesize
that this restriction occurs at the level of packaging, which is
currently being investigated. Insert stability was investigated for the
CAT gene and found to be remarkably high. Deletion of foreign
sequence was not observed, and the accumulation of point
mutations was not rapid, such that after seven passages each gene
had on average a single nucleotide substitution which, in the 25
plaques examined, did not affect protein expression or enzymatic
activity. The gene deletions and insertions described above each
resulted in a change in genome length and in the number of
expressed mRNAs. We are examining transcription by these viruses
to determine what effects, in any, these changes have on sequential
transcription. We also are examining the effects of introducing
longer-than-natural intergenic regions as possible attenuating
mutations and to shed light on polymerase activities at the gene
junctions. We previously showed that one of the attenuating
mutations of the biologically-derived cptsRSV vaccine virus is a
single nucleotide change (A9 to G, negative-sense) in the GS signal
of the M2 gene. This mutation has now been inserted into the GS
signal of the NS1, or NS2, or both genes, and evaluation of the
resulting mutants is in progress. We previously showed that the
naturally-occurring GE signals for these two genes are only 60% as
efficient in directing transcriptional termination as are the signals for
the other eight RSV genes. This is associated with an increased
frequency of synthesis of the following readthrough mRNAs:
NS1-NS2, NS2-N, NS1-NS2-N. Since internal ORFs of eukaryotic
mRNAs are not efficiently translated, this would have the effect of
reducing the amount of mRNA capable of synthesizing the NS2 and
N proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6098950
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
STRUCTURAL ANALYSIS OF THE GENOME OF RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288840
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288863
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6431577
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:6985263
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7192840
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
-
批准号:8745290
-
项目类别:
-
资助金额:$191.68万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
-
批准号:8946258
-
项目类别:
-
资助金额:$107.29万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
-
批准号:9161440
-
项目类别:
-
资助金额:$152.01万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:9566628
-
项目类别:
-
资助金额:$231.32万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:8336177
-
项目类别:
-
资助金额:$166.16万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
-
批准号:10014018
-
项目类别:
-
资助金额:$154.41万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7732445
-
项目类别:
-
资助金额:$100.86万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:7964502
-
项目类别:
-
资助金额:$142.51万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
-
批准号:8156824
-
项目类别:
-
资助金额:$149.67万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
REPLICATION,VIRULENCE & IMMUNOGENICITY IN RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288842
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
In Vitro Models of Paramyxovirus Infection
-
批准号:6985695
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7964244
-
项目类别:
-
资助金额:$54.57万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Human Respiratory Syncytial Virus Biology And Vaccine Development
-
批准号:8336046
-
项目类别:
-
资助金额:$127.27万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Clinical Trials of Parainfluenza and Respiratory Syncytial Virus Vaccines
-
批准号:8336038
-
项目类别:
-
资助金额:$274.77万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位: